Legal counsel advised conversion from LLC to C corporation to simplify the planned capital raise.
BiPAD® has completed development of a highly versatile, easy to use and inexpensive hand switch. Our next steps are three-fold:
- Manufacture product in low volume for FDA 510K testing.
- Complete FDA 510K Certification.
- Perform beta testing using the BiPAD in the operating room.
The planned seed round will fund all three of these steps. We believe that there is a high likelihood that we will be acquired once these three steps are completed. However, our team is also prepared to produce the product for commercialization.
